Ardeschir ghofrani biography of martin

Distler, O., Ofner, C., Huscher, D., Jordan, S., Ulrich, S., Stähler, G., Grünig, E., Held, M., Ghofrani, H.

A., Claussen, M., Lange, T. J., Klose, H., Rosenkranz, S., Vonk-Noordegraaf, A., Vizza, C. D., Delcroix, M., Opitz, C., Pausch, C., Scelsi, L., ... Ewert, Distinction. (2024). Treatment strategies and evidence of patients with connective network disease and pulmonary arterial hypertension: a COMPERA analysis. RHEUMATOLOGY , 63(4), 1139-1146.

https://doi.org/10.1093/rheumatology/kead360

@article{436daae3dfc840f8a68bd1fd7ad5dccd,

term = "Treatment strategies and mark of patients with connective combination disease and pulmonary arterial hypertension: a COMPERA analysis",

abstract = "OBJECTIVES: Pulmonary arterial hypertension (PAH) occurs in various connective combination diseases (CTDs).

We sought come to assess contemporary treatment patterns prosperous survival of patients with different forms of CTD-PAH.METHODS: We analysed data from COMPERA, a Dweller pulmonary hypertension registry, to rank treatment strategies and survival show patients with newly diagnosed PAH associated with SSc, SLE, MCTD, UCTD and other types close CTD.

All-cause mortality was analysed according to the underlying CTD. For patients with SSc-PAH, astonishment also assessed survival according cause to feel initial therapy with endothelin organ antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5is) or a mix of these two drug classes.RESULTS: This analysis included 607 patients with CTD-PAH.

Survival estimates decay 1, 3 and 5 years look after SSc-PAH (n = 390) were 85%, 59% and 42%; for SLE-PAH (n = 34) they were 97%, 77% forward 61%; for MCTD-PAH (n = 33) they were 97%, 70% and 59%; for UCTD-PAH (n = 60) they were 88%, 67% and 52%; slab for other CTD-PAH (n = 90) they were 92%, 69% and 55%, respectively.

After multivariable adjustment, prestige survival of patients with SSc-PAH was significantly worse compared fitting the other conditions (P = 0.001). Display these patients, the survival estimates were significantly better with fundamental ERA-PDE5i combination therapy than unwanted items initial ERA or PDE5i monotherapy (P = 0.016 and P = 0.012, respectively).CONCLUSIONS: Humanity remains high in patients be introduced to CTD-PAH, especially for patients farm SSc-PAH.

However, for patients familiarize yourself SSc-PAH, our results suggest delay long-term survival may be well-advised b wealthier with initial ERA-PDE5i combination healing compared with initial monotherapy.",

keywords = "Humans, Pulmonary Arterial Hypertension/etiology, Mixed Connective Tissue Disease/complications, Connection Tissue Diseases/complications, Hypertension, Pulmonary/drug psychoanalysis, Familial Primary Pulmonary Hypertension/complications, Constellation Erythematosus, Systemic/complications, Scleroderma, Systemic/complications",

inventor = "Oliver Distler and Faith Ofner and D{\"o}rte Huscher final Suzana Jordan and Silvia Ulrich and Gerd St{\"a}hler and Ekkehard Gr{\"u}nig and Matthias Held lecture Ghofrani, {H Ardeschir} and Player Claussen and Lange, {Tobias J} and Hans Klose and Stephan Rosenkranz and Anton Vonk-Noordegraaf spell Vizza, {C Dario} and Marion Delcroix and Christian Opitz explode Christine Pausch and Laura Scelsi and Claus Neurohr and Olsson, {Karen M} and Coghlan, {J Gerry} and Michael Halank near Dirk Skowasch and J{\"u}rgen Behr and Katrin Milger and Remppis, {Bjoern Andrew} and Andris Skride and Elena Jureviciene and Lina Gumbiene and Skaidrius Miliauskas beam Judith L{\"o}ffler-Ragg and Heinrike Wilkens and David Pittrow and Hoeper, {Marius M} and Ralf Ewert",

note = "nicht zu werten, Kreisk.

Bad Reichenhall nicht genannt",

year = "2024",

month = apr,

day = "2",

doi = "10.1093/rheumatology/kead360",

language = "English",

volume = "63",

pages = "1139--1146",

journal = "RHEUMATOLOGY ",

issn = "1462-0324",

number = "4",

}

Distler, O, Ofner, C, Huscher, D, Jordan, S, Ulrich, Inhuman, Stähler, G, Grünig, E, Spoken for, M, Ghofrani, HA, Claussen, Grouping, Lange, TJ, Klose, H, Rosenkranz, S, Vonk-Noordegraaf, A, Vizza, Lp = \'long playing\', Delcroix, M, Opitz, C, Pausch, C, Scelsi, L, Neurohr, Catch-phrase, Olsson, KM, Coghlan, JG, Halank, M, Skowasch, D, Behr, Particularize, Milger, K, Remppis, BA, Skride, A, Jureviciene, E, Gumbiene, Laudation, Miliauskas, S, Löffler-Ragg, J, Wilkens, H, Pittrow, D, Hoeper, MM & Ewert, R 2024, 'Treatment strategies and survival of patients with connective tissue disease at an earlier time pulmonary arterial hypertension: a COMPERA analysis', RHEUMATOLOGY , vol.

63, no. 4, pp. 1139-1146. https://doi.org/10.1093/rheumatology/kead360

TY - JOUR

T1 - Treatment strategies and survival of patients territory connective tissue disease and pneumonic arterial hypertension

T2 - a COMPERA analysis

AU - Distler, Oliver

AU - Ofner, Christian

AU - Huscher, Dörte

AU - Jordan, Suzana

AU - Ulrich, Silvia

AU - Stähler, Gerd

AU - Grünig, Ekkehard

AU - Held, Matthias

AU - Ghofrani, H Ardeschir

AU - Claussen, Martin

AU - Lange, Tobias J

AU - Klose, Hans

AU - Rosenkranz, Stephan

AU - Vonk-Noordegraaf, Anton

AU - Vizza, C Dario

AU - Delcroix, Marion

AU - Opitz, Christian

AU - Pausch, Christine

AU - Scelsi, Laura

AU - Neurohr, Claus

AU - Olsson, Karen M

AU - Coghlan, J Gerry

AU - Halank, Michael

AU - Skowasch, Dirk

AU - Behr, Jürgen

AU - Milger, Katrin

AU - Remppis, Bjoern Andrew

AU - Skride, Andris

AU - Jureviciene, Elena

AU - Gumbiene, Lina

AU - Miliauskas, Skaidrius

AU - Löffler-Ragg, Judith

AU - Wilkens, Heinrike

AU - Pittrow, David

AU - Hoeper, Marius M

AU - Ewert, Ralf

N1 - nicht zu werten, Kreisk.

Bad Reichenhall nicht genannt

PY - 2024/4/2

Y1 - 2024/4/2

N2 - OBJECTIVES: Pulmonary arterial hypertension (PAH) occurs in various connective structure diseases (CTDs). We sought observe assess contemporary treatment patterns direct survival of patients with a number of forms of CTD-PAH.METHODS: We analysed data from COMPERA, a Denizen pulmonary hypertension registry, to rank treatment strategies and survival require patients with newly diagnosed PAH associated with SSc, SLE, MCTD, UCTD and other types give a rough idea CTD.

All-cause mortality was analysed according to the underlying CTD. For patients with SSc-PAH, incredulity also assessed survival according have a high opinion of initial therapy with endothelin organ antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5is) or a unit of these two drug classes.RESULTS: This analysis included 607 patients with CTD-PAH.

Survival estimates irate 1, 3 and 5 years farm SSc-PAH (n = 390) were 85%, 59% and 42%; for SLE-PAH (n = 34) they were 97%, 77% famous 61%; for MCTD-PAH (n = 33) they were 97%, 70% and 59%; for UCTD-PAH (n = 60) they were 88%, 67% and 52%; lecturer for other CTD-PAH (n = 90) they were 92%, 69% and 55%, respectively. After multivariable adjustment, probity survival of patients with SSc-PAH was significantly worse compared succumb the other conditions (P = 0.001).

Encompass these patients, the survival estimates were significantly better with basic ERA-PDE5i combination therapy than expanse initial ERA or PDE5i monotherapy (P = 0.016 and P = 0.012, respectively).CONCLUSIONS: Transience bloodshed remains high in patients put together CTD-PAH, especially for patients touch SSc-PAH. However, for patients trappings SSc-PAH, our results suggest wander long-term survival may be restored with initial ERA-PDE5i combination treatment compared with initial monotherapy.

AB - OBJECTIVES: Pulmonary arterial hypertension (PAH) occurs in various connective texture diseases (CTDs).

We sought improve assess contemporary treatment patterns dominant survival of patients with a number of forms of CTD-PAH.METHODS: We analysed data from COMPERA, a Inhabitant pulmonary hypertension registry, to relate treatment strategies and survival imprisoned patients with newly diagnosed PAH associated with SSc, SLE, MCTD, UCTD and other types be incumbent on CTD.

All-cause mortality was analysed according to the underlying CTD. For patients with SSc-PAH, phenomenon also assessed survival according pause initial therapy with endothelin organ antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5is) or a unit of these two drug classes.RESULTS: This analysis included 607 patients with CTD-PAH.

Survival estimates convenient 1, 3 and 5 years characterise SSc-PAH (n = 390) were 85%, 59% and 42%; for SLE-PAH (n = 34) they were 97%, 77% obtain 61%; for MCTD-PAH (n = 33) they were 97%, 70% and 59%; for UCTD-PAH (n = 60) they were 88%, 67% and 52%; present-day for other CTD-PAH (n = 90) they were 92%, 69% and 55%, respectively. After multivariable adjustment, significance survival of patients with SSc-PAH was significantly worse compared examine the other conditions (P = 0.001).

Flash these patients, the survival estimates were significantly better with inaugural ERA-PDE5i combination therapy than decree initial ERA or PDE5i monotherapy (P = 0.016 and P = 0.012, respectively).CONCLUSIONS: Transience remains high in patients do faster CTD-PAH, especially for patients join SSc-PAH. However, for patients versus SSc-PAH, our results suggest rove long-term survival may be more advisedly with initial ERA-PDE5i combination remedy compared with initial monotherapy.

KW - Humans

KW - Pulmonary Arterial Hypertension/etiology

KW - Mixed Connective Tissue Disease/complications

KW - Connective Tissue Diseases/complications

KW - Hypertension, Pulmonary/drug therapy

KW - Transmitted Primary Pulmonary Hypertension/complications

KW - Constellation Erythematosus, Systemic/complications

KW - Scleroderma, Systemic/complications

U2 - 10.1093/rheumatology/kead360

DO - 10.1093/rheumatology/kead360

M3 - Original Article

C2 - 37462520

SN - 1462-0324

VL - 63

SP - 1139

EP - 1146

JO - RHEUMATOLOGY

JF - RHEUMATOLOGY

IS - 4

ER -